Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development

"The World's Most Prevalent Sexually-Transmitted Bacteria

Phase II STTR from the National Institute of Allergy and Infectious Diseases

IRVINE, Calif., Sept. 21 /PRNewswire/ -- Antigen Discovery, Inc. ('ADi', formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009"

Chlamydia rise a risk to pregnancies | The Australian

"Latest figures on sexually transmitted infections in Australia, to be released today, show that, although better-known problems such as HIV have stabilised, chlamydia is continuing its upward trajectory.

The bacterial infection passes unnoticed in up to 70 per cent of people, and is often considered a mild illness even when it does cause symptoms."